These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 6332862)

  • 1. Immunotherapy of lymphoid and nonlymphoid tumors with monoclonal anti-Lyt-1 antibodies.
    Hollander N
    J Immunol; 1984 Nov; 133(5):2801-5. PubMed ID: 6332862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immunotherapeutic effect of anti Lyt-1 antibodies on local and metastatic tumor growth.
    Hollander N
    Adv Exp Med Biol; 1985; 186():819-26. PubMed ID: 3876726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
    Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE
    J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
    Fujiwara H; Fukuzawa M; Yoshioka T; Nakajima H; Hamaoka T
    J Immunol; 1984 Sep; 133(3):1671-6. PubMed ID: 6205091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy of murine leukemias by monoclonal antibody. I. Effect of passively administered antibody on growth of transplanted tumor cells.
    Kirch ME; Hammerling U
    J Immunol; 1981 Aug; 127(2):805-10. PubMed ID: 6788849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immunosuppressive effect of monoclonal anti-Lyt-1.1 antibodies in vivo.
    Michaelides M; Hogarth PM; McKenzie IF
    Eur J Immunol; 1981 Dec; 11(12):1005-12. PubMed ID: 6173235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The functional association of Lyt antigens with lymphokine production.
    Hollander N; Shepshalovich J
    Immunology; 1985 Jan; 54(1):25-33. PubMed ID: 2579021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immunotherapeutic effects in tumor-bearing mice of Ly-6 monoclonal antibodies.
    Lu L; Palladino MA; DeLeo AB
    J Immunol; 1989 Jan; 142(2):719-25. PubMed ID: 2783443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The immunological basis of tumor rejection: the absolute dependence of the effector arm on sensitized T cells after chemoimmunotherapy of a murine sarcoma.
    Evans R; Duffy T
    J Immunol; 1985 Jun; 134(6):4255-60. PubMed ID: 3872913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A role for Lyt-2+ T cells in resistance to cutaneous leishmaniasis in immunized mice.
    Farrell JP; Muller I; Louis JA
    J Immunol; 1989 Mar; 142(6):2052-6. PubMed ID: 2784148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vivo modulation of thymus-derived lymphocytes with monoclonal antibodies in mice. I. Effect of anti-Thy-1 antibody on the tissue distribution of lymphocytes.
    Le Gros GS; Prestidge RL; Watson JD
    Immunology; 1983 Dec; 50(4):537-46. PubMed ID: 6606612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. H-40, an antigen controlled by an Igh-linked gene and recognized by cytotoxic T lymphocytes. II. Recognition of H-40 as a tumor antigen in leukemic animals.
    Henderson LA; Ciavarra R; Riblet R; Forman J
    J Immunol; 1984 Nov; 133(5):2778-85. PubMed ID: 6434638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory role of T lymphocytes and NK cells in tumor allograft development.
    Sobotková E; Nouza K
    Neoplasma; 1993; 40(2):75-80. PubMed ID: 8350958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of a common antigen on murine B cells and Lyt-2+ T cells by a rat monoclonal antibody, 14D10.
    Kung JT; Sharrow SO; Mage MG; Paul WE
    J Immunol; 1982 Jul; 129(1):81-6. PubMed ID: 6806368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rat T lymphocyte antigens comparable with mouse Lyt-1 and Lyt-2,3 antigenic systems: characterization by monoclonal antibodies.
    Matsuura A; Ishii Y; Yuasa H; Narita H; Kon S; Takami T; Kikuchi K
    J Immunol; 1984 Jan; 132(1):316-22. PubMed ID: 6606669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
    Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
    Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
    Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
    Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models.
    Kim S; Fridlender ZG; Dunn R; Kehry MR; Kapoor V; Blouin A; Kaiser LR; Albelda SM
    J Immunother; 2008 Jun; 31(5):446-57. PubMed ID: 18463540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capacity of purified unprimed Lyt-2+ cells to reject Ia- H-2-different tumor cells in the Winn assay.
    Sprent J; Schaefer M
    J Immunol; 1988 May; 140(9):2899-902. PubMed ID: 3258888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
    Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
    Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.